Wednesday, November 19, 2025 CCTG BLC4 (SWOG S1605) Urine Tumor DNA to Stratify the Risk of Recurrence This study demonstrates that urine tumor DNA profiling can be used to stratify the risk of recurrence in patients after treatment with atezolizumab for bacillus Calmette-Guérin–unresponsive non–muscle-invasive bladder cancer. St-Laurent M-P, Singh P, McConkey DJ, Lucia MS, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Meeks JJ, Caruso VM, Ward CT, Mazzarella BC, Phillips KG, Bicocca VT, Levin TG, Lerner SP, Black PC. Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer. European Urology 88: 430-434. 2025. https://www.sciencedirect.com/science/article/pii/S0302283825002179
